The circadian timing system in clinical oncology

References

• Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010; 50:377–421.
   PubMed Web of Science ®Google Scholar
• Dibner C, Schibler U, Albrecht U. The Mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.
   PubMed Web of Science ®Google Scholar
• Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445–62.
   PubMed Web of Science ®Google Scholar
• Doherty CJ, Kay SA. Circadian control of global gene expression patterns. Annu Rev Genet. 2010;44:419–44.
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Gooley JJ. Sleep and circadian rhythms in humans. Cold Spring Harb Symp Quant Biol. 2007;72:579–97.
   PubMedGoogle Scholar
• Innominato PF, Levi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev. 2010;62:979–1001.
   PubMed Web of Science ®Google Scholar
• Reddy AB, O’Neill JS. Healthy clocks, healthy body, healthy mind. Trends Cell Biol. 2010;20:36–44.
   PubMed Web of Science ®Google Scholar
• Shibata S, Tahara Y, Hirao A. The adjustment and manipulation of biological rhythms by light, nutrition, and abused drugs. Adv Drug Deliv Rev. 2010;62:918–27.
   PubMed Web of Science ®Google Scholar
• Lévi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.
   PubMed Web of Science ®Google Scholar
• Roenneberg T, Kantermann T, Juda M, Vetter C, Allebrandt KV. Light and the human circadian clock. Handb Exp Pharmacol. 2013;(217):311–31.
   PubMedGoogle Scholar
• Roenneberg T, Merrow M. Entrainment of the human circadian clock. Cold Spring Harb Symp Quant Biol. 2007;72:293–9.
   PubMedGoogle Scholar
• Moore RY. The suprachiasmatic nucleus and the circadian timing system. Prog Mol Biol Transl Sci. 2013;119:1–28.
   PubMed Web of Science ®Google Scholar
• Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U. The mammalian circadian timing system: from gene expression to physiology. Chromosoma. 2004;113:103–12.
   PubMed Web of Science ®Google Scholar
• Schibler U, Sassone-Corsi P. A web of circadian pacemakers. Cell. 2002;111:919–22.
   PubMed Web of Science ®Google Scholar
• Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690–7.
   PubMed Web of Science ®Google Scholar
• Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ, et al. Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst. 2005;97:507–17.
   PubMed Web of Science ®Google Scholar
• Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, et al. Effects of chronic jet lag on tumor progression in mice. Cancer Res. 2004;64:7879–85.
   PubMed Web of Science ®Google Scholar
• Filipski E, Levi F. Circadian disruption in experimental cancer processes. Integr Cancer Ther. 2009;8:298–302.
   PubMed Web of Science ®Google Scholar
• Brown SA, Azzi A. Peripheral circadian oscillators in mammals. Handb Exp Pharmacol. 2013;(217):45–66.
   PubMedGoogle Scholar
• Nagoshi E, Saini C, Bauer C, Laroche T, Naef F, Schibler U. Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell. 2004;119:693–705.
   PubMed Web of Science ®Google Scholar
• Miller BH, McDearmon EL, Panda S, Hayes KR, Zhang J, Andrews JL, et al. Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A. 2007;104:3342–7.
   PubMed Web of Science ®Google Scholar
• Lévi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol. 2007; 72:465–75.
   PubMedGoogle Scholar
• Hunt T, Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell. 2007;129:461–4.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255–9.
   PubMed Web of Science ®Google Scholar
• Geyfman M, Kumar V, Liu Q, Ruiz R, Gordon W, Espitia F, et al. Brain and muscle Arnt-like protein-1 (BMAL1) controls circadian cell proliferation and susceptibility to UVB-induced DNA damage in the epidermis. Proc Natl Acad Sci U S A. 2012;109:11758–63.
   PubMed Web of Science ®Google Scholar
• Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22: 375–82.
   PubMed Web of Science ®Google Scholar
• Gery S, Koeffler HP. The role of circadian regulation in cancer. Cold Spring Harb Symp Quant Biol. 2007;72:459–64.
   PubMedGoogle Scholar
• Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013;119:221–82.
   PubMed Web of Science ®Google Scholar
• Buhr ED, Takahashi JS. Molecular components of the mammalian circadian clock. Handb Exp Pharmacol. 2013;(217):3–27.
   PubMedGoogle Scholar
• O’Neill JS, Maywood ES, Hastings MH. Cellular mechanisms of circadian pacemaking: beyond transcriptional loops. Handb Exp Pharmacol. 2013;(217):67–103.
   Google Scholar
• Ortiz-Tudela E, Mteyrek A, Ballesta A, Innominato PF, Lévi F. Cancer chronotherapeutics: experimental, theoretical, and clinical aspects. Handb Exp Pharmacol. 2013;(217):261–88.
   PubMedGoogle Scholar
• Zhang EE, Kay SA. Clocks not winding down: unravelling circadian networks. Nat Rev Mol Cell Biol. 2010;11:764–76.
   PubMed Web of Science ®Google Scholar
• Kornmann B, Schaad O, Reinke H, Saini C, Schibler U. Regulation of circadian gene expression in liver by systemic signals and hepatocyte oscillators. Cold Spring Harb Symp Quant Biol. 2007;72:319–30.
   PubMedGoogle Scholar
• Minami Y, Ode KL, Ueda HR. Mammalian circadian clock: the roles of transcriptional repression and delay. Handb Exp Pharmacol. 2013;(217):359–77.
   PubMedGoogle Scholar
• Ukai H, Ueda HR. Systems biology of mammalian circadian clocks. Annu Rev Physiol. 2010;72:579–603.
   PubMedGoogle Scholar
• Ueda HR. Systems biology of mammalian circadian clocks. Cold Spring Harb Symp Quant Biol. 2007;72:365–80.
   PubMedGoogle Scholar
• Delaunay F, Laudet V. Circadian clock and microarrays: mammalian genome gets rhythm. Trends Genet. 2002;18:595–7.
   PubMed Web of Science ®Google Scholar
• Mauvoisin D, Wang J, Jouffe C, Martin E, Atger F, Waridel P, et al. Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. Proc Natl Acad Sci U S A. 2014;111:167–72.
   PubMed Web of Science ®Google Scholar
• Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA. The human circadian metabolome. Proc Natl Acad Sci U S A. 2012;109:2625–9.
   PubMed Web of Science ®Google Scholar
• Grechez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F. The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem. 2008;283:4535–42.
   PubMed Web of Science ®Google Scholar
• Dallmann R, Brown SA, Gachon F. Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 2014; 54:339–61.
   PubMed Web of Science ®Google Scholar
• Paschos GK, Baggs JE, Hogenesch JB, FitzGerald GA. The role of clock genes in pharmacology. Annu Rev Pharmacol Toxicol. 2010; 50:187–214.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Levi F. Cancer chronotherapy: principles, applications, and perspectives. Cancer. 2003;97:155–69.
   PubMed Web of Science ®Google Scholar
• Levi F. Circadian chronotherapy for human cancers. Lancet Oncol. 2001;2:307–15.
   PubMed Web of Science ®Google Scholar
• Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.
   PubMed Web of Science ®Google Scholar
• Bertrand PP, Polglaz KE, Bertrand RL, Sandow SL, Pozo MJ. Detection of melatonin production from the intestinal epithelium using electrochemical methods. Curr Pharm Des. 2013 Nov 18. [Epub ahead of print]
   PubMedGoogle Scholar
• Li XM, Liu XH, Filipski E, Metzger G, Delagrange P, Jeanniot JP, et al. Relationship of atypical melatonin rhythm with two circadian clock outputs in B6D2F(1) mice. Am J Physiol Regul Integr Comp Physiol. 2000;278:R924–30.
   PubMed Web of Science ®Google Scholar
• Chang A-M, Santhi N, St Hilaire M, Gronfier C, Bradstreet DS, Duffy JF, et al. Human responses to bright light of different durations. J Physiol. 2012;590(Pt 13):3103–12.
   PubMedGoogle Scholar
• Sainz RM, Mayo JC, Tan D, León J, Manchester L, Reiter RJ. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. Prostate. 2005;63:29–43.
   PubMedGoogle Scholar
• Stevens RG, Brainard GC, Blask DE, Lockley SW, Motta ME. Breast cancer and circadian disruption from electric lighting in the modern world. CA Cancer J Clin. 2014:64:207–18.
   PubMed Web of Science ®Google Scholar
• Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther. 2009;8:347–53.
   PubMed Web of Science ®Google Scholar
• Lahti T, Merikanto I, Partonen T. Circadian clock disruptions and the risk of cancer. Ann Med. 2012;44:847–53.
   PubMed Web of Science ®Google Scholar
• Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Langouet AM, Claustrat B, Bogdan A, Marion S, Waterhouse J, et al. Marker rhythms of circadian system function: a study of patients with metastatic colorectal cancer and good performance status. Chronobiol Int. 2002;19:141–55.
   PubMed Web of Science ®Google Scholar
• Nader N, Chrousos GP, Kino T. Interactions of the circadian CLOCK system and the HPA axis. Trends Endocrinol Metab. 2010;21:277–86.
   PubMed Web of Science ®Google Scholar
• Kudielka BM, Federenko IS, Hellhammer DH, Wüst S. Morningness and eveningness: the free cortisol rise after awakening in “early birds” and “night owls”. Biol Psychol. 2006;72:141–6.
   PubMed Web of Science ®Google Scholar
• Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol. 2009;72:67–73.
   PubMed Web of Science ®Google Scholar
• Sephton S, Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?Brain Behav Immun. 2003;17:321–8.
   PubMed Web of Science ®Google Scholar
• Eismann EA, Lush E, Sephton SE. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. Psychoneuroendocrinology. 2010;35:963–76.
   PubMed Web of Science ®Google Scholar
• Evans JA, Davidson AJ. Health consequences of circadian disruption in humans and animal models. Prog Mol Biol Transl Sci. 2013;119: 283–323.
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, Fliers E. Daily regulation of hormone profiles. Handb Exp Pharmacol. 2013;(217):185–226.
   PubMedGoogle Scholar
• Weinrib AZ, Sephton SE, Degeest K, Penedo F, Bender D, Zimmerman B, et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010; 116:4410–9.
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008;26:4820–7.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994–1000.
   PubMed Web of Science ®Google Scholar
• Sephton SE, Lush E, Dedert EA, Floyd AR, Rebholz WN, Dhabhar FS, et al. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav Immun. 2013;30(Suppl):S163–70.
   Google Scholar
• Mormon MC, Bogdan A, Cormont S, Touitou Y, Levi F. Cortisol diurnal variation in blood and saliva of patients with metastatic colorectal cancer: relevance for clinical outcome. Anticancer Res. 2002;22:1243–9.
   PubMed Web of Science ®Google Scholar
• Spiegel D, Dugué P-A, Innominato PF, Karaboué A, Dispersyn G, Parganiha A, et al. Circadian rest-activity rhythm as a predictor of survival in metastatic colorectal cancer. 2012 ASCO Annual Meeting. J Clin Oncol. 2012;30:(suppl; abstr e14006).
   Google Scholar
• Levi F, Parganiha A, Karaboué A, Innominato PF, Dispersyn G, Giacchetti S, et al. Circadian robustness, an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2012;30:(suppl 4; abstr 464).
   Google Scholar
• Ortiz-Tudela E, Martinez-Nicolas A, Campos M, Rol MA, Madrid JA. A new integrated variable based on thermometry, actimetry and body position (TAP) to evaluate circadian system status in humans. PLoS Comput Biol. 2010;6:e1000996.
   PubMed Web of Science ®Google Scholar
• Roche V, Mohamad-Djafari A, Innominato PF, Karaboue A, Gorbach AM, Lévi FA. Thoracic surface temperature rhythms as circadian biomarkers for cancer chronotherapy. Chronobiol Int. 2014;31:409–20.
   PubMed Web of Science ®Google Scholar
• Waterhouse J, Fukuda Y, Morita T. Daily rhythms of the sleep-wake cycle. J Physiol Anthropol. 2012;31:5.
   PubMed Web of Science ®Google Scholar
• Okamoto-Mizuno K, Mizuno K. Effects of thermal environment on sleep and circadian rhythm. J Physiol Anthropol. 2012;31:14.
   PubMed Web of Science ®Google Scholar
• Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev. 2010;90:1063–102.
   PubMed Web of Science ®Google Scholar
• Brown SA, Zumbrunn G, Fleury-Olela F, Preitner N, Schibler U. Rhythms of mammalian body temperature can sustain peripheral circadian clocks. Curr Biol. 2002;12:1574–83.
   PubMed Web of Science ®Google Scholar
• Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010;330:1349–54.
   PubMed Web of Science ®Google Scholar
• Prolo LM, Takahashi JS, Herzog ED. Circadian rhythm generation and entrainment in astrocytes. J Neurosci. 2005;25:404–8.
   PubMed Web of Science ®Google Scholar
• Teunissen LPJ, de Haan A, de Koning JJ, Daanen HAM. Telemetry pill versus rectal and esophageal temperature during extreme rates of exercise-induced core temperature change. Physiol Meas. 2012;33:915–24.
   PubMed Web of Science ®Google Scholar
• Scully CG, Karaboue A, Liu WM, Meyer J, Innominato PF, Chon KH, et al. Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients. Interface Focus. 2011;1:48–60.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26:342–92.
   PubMed Web of Science ®Google Scholar
• Berger AM, Wielgus KK, Young-McCaughan S, Fischer P, Farr L, Lee KA. Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 2008;36:191–9.
   PubMed Web of Science ®Google Scholar
• Hall JC, Chang DC, Dolezelova E. Principles and problems revolving around rhythm-related genetic variants. Cold Spring Harb Symp Quant Biol. 2007;72:215–32.
   PubMedGoogle Scholar
• Minors D, Akerstedt T, Atkinson G, Dahlitz M, Folkard S, Levi F, et al. The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiol Int. 1996;13: 27–34.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038–45.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, et al. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 2009;69:4700–7.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Bjarnason GA, Focan C, Garufi C, Coudert B, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012;131:2684–92.
   PubMed Web of Science ®Google Scholar
• Martinez-Nicolas A, Ortiz-Tudela E, Madrid JA, Rol MA. Crosstalk between environmental light and internal time in humans. Chronobiol Int. 2011;28:617–29.
   PubMed Web of Science ®Google Scholar
• Foster RG, Wulff K. The rhythm of rest and excess. Nat Rev Neurosci. 2005;6:407–14.
   PubMed Web of Science ®Google Scholar
• Van den Heiligenberg S, Deprés-Brummer P, Barbason H, Claustrat B, Reynes M, Lévi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci. 1999;64:2523–34.
   PubMed Web of Science ®Google Scholar
• Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res. 2009;680:95–105.
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41–50.
   PubMed Web of Science ®Google Scholar
• Filipski E, Li XM, Levi F. Disruption of circadian coordination and malignant growth. Cancer Causes Control. 2006;17:509–14.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100: 57–70.
   PubMed Web of Science ®Google Scholar
• Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. Night work and breast cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2005;41:2023–32.
   PubMed Web of Science ®Google Scholar
• Stevens RG, Hansen J, Costa G, Haus E, Kauppinen T, Aronson KJ, et al. Considerations of circadian impact for defining “shift work” in cancer studies: IARC Working Group Report. Occup Env Med. 2011;68:154–62.
   PubMed Web of Science ®Google Scholar
• Stevens RG. Working against our endogenous circadian clock: breast cancer and electric lighting in the modern world. Mutat Res. 2009;679:6–8.
   Google Scholar
• Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S, et al. Cancer-related fatigue and sleep disorders. Oncologist. 2007;12(Suppl 1):35–42.
   PubMed Web of Science ®Google Scholar
• Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26:971–82.
   PubMed Web of Science ®Google Scholar
• Bower JE. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol. 2008;26:768–77.
   PubMed Web of Science ®Google Scholar
• Bower JE. Prevalence and causes of fatigue after cancer treatment: the next generation of research. J Clin Oncol. 2005;23:8280–2.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J. Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiol Int. 2002;19:313–23.
   PubMed Web of Science ®Google Scholar
• Bower JE, Ganz PA, Dickerson SS, Petersen L, Aziz N, Fahey JL. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology. 2005;30:92–100.
   PubMed Web of Science ®Google Scholar
• Bower JE, Ganz PA, Tao ML, Hu W, Belin TR, Sepah S, et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res. 2009;15:5534–40.
   PubMed Web of Science ®Google Scholar
• Rich T, Innominato PF, Boerner J, Mormont MC, Iacobelli S, Baron B, et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:1757–64.
   PubMed Web of Science ®Google Scholar
• Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12:2759–66.
   PubMed Web of Science ®Google Scholar
• Cormie P, Newton RU, Taaffe DR, Spry N, Galvão DA. Exercise therapy for sexual dysfunction after prostate cancer. Nat Rev Urol. 2013;10:731–6.
   PubMed Web of Science ®Google Scholar
• Van Gerpen RE, Becker BJ. Development of an evidence-based exercise and education cancer recovery program. Clin J Oncol Nurs. 2013;17:539–43.
   PubMedGoogle Scholar
• Minton O, Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol. 2009;20:17–25.
   PubMed Web of Science ®Google Scholar
• Payne JK. Altered circadian rhythms and cancer-related fatigue outcomes. Integr Cancer Ther. 2011;10:221–33.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Mormont MC, Rich TA, Waterhouse J, Levi FA, Bjarnason GA. Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches. Integr Cancer Ther. 2009;8:361–70.
   PubMed Web of Science ®Google Scholar
• Palesh O, Peppone L, Innominato PF, Janelsins M, Jeong M, Sprod L, et al. Prevalence, putative mechanisms and management of sleep problems during chemotherapy. Nat Sci Sleep. 2012;4:151–62.
   PubMedGoogle Scholar
• Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol. 2010;28:292–8.
   PubMed Web of Science ®Google Scholar
• Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19:895–908.
   PubMed Web of Science ®Google Scholar
• Palesh OG, Collie K, Batiuchok D, Tilston J, Koopman C, Perlis ML, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 2007;75:37–44.
   PubMed Web of Science ®Google Scholar
• Palesh O, Aldridge Gerry A, Zeitzer JM, Koopman C, Jo B, Neri E, et al. Actigraphy measured sleep disruption as a predictor of survival in advanced breast cancer. 2013 ASCO Annual Meeting. J Clin Oncol. 2013;31:(suppl; abstr 9532).
   Google Scholar
• Spiegel D. Losing sleep over cancer. J Clin Oncol. 2008;26:2431–2.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Palesh O, Dhabhar FS, Levi F, Spiegel D. Regulation of circadian rhythms and hypothalamic-pituitary-adrenal axis: an overlooked interaction in cancer. Lancet Oncol. 2010;11:816–17.
   PubMed Web of Science ®Google Scholar
• Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, et al. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One. 2012;7:e42324.
   Web of Science ®Google Scholar
• Palesh O, Bjarnason G, Deguzman C, Haitz K, Giacchetti S, Spiegel D, et al. Subjective sleep problems predict survival in 240 patients with metastatic colorectal cancer. 2013 MASCC Annual Meeting. Berlin, Germany; June 27–29, 2013.
   Google Scholar
• Hahm B, Jo B, Dhabhar F, Palesh O, Aldridge-Gerry A, Bajestan S, et al. Bedtime misalignment and progression of breast cancer. Chronobiol Int. 2014;31:214–21.
   PubMed Web of Science ®Google Scholar
• Coudert B, Focan C, Donato di Paola E, Levi F. It's time for chronotherapy!Eur J Cancer. 2002;38(Suppl 4):S50–3.
   Google Scholar
• Giacchetti S, Dugue PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, et al. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 2012;23:3110–6.
   PubMed Web of Science ®Google Scholar
• Ahowesso C, Li XM, Zampera S, Peteri-Brunbäck B, Dulong S, Beau J, et al. Sex and dosing-time dependencies in irinotecan-induced circadian disruption. Chronobiol Int. 2011;28:458–70.
   PubMed Web of Science ®Google Scholar
• Li X-M, Mohammad-Djafari A, Dumitru M, Dulong S, Filipski E, Siffroi-Fernandez S, et al. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013;73:7176–88.
   PubMed Web of Science ®Google Scholar
• Lévi F, Zidani R, Misset JL. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet. 1997;350:681–6.
   PubMed Web of Science ®Google Scholar
• Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86:1608–17.
   PubMed Web of Science ®Google Scholar
• Ohdo S. Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet. 2007;22:3–14.
   PubMed Web of Science ®Google Scholar
• Musiek ES, Fitzgerald GA. Molecular clocks in pharmacology. Handb Exp Pharmacol. 2013;(217):243–60.
   PubMedGoogle Scholar
• Sancar A, Lindsey-Boltz LA, Kang T-H, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 2010;584:2618–25.
   PubMed Web of Science ®Google Scholar
• Plikus MV, Vollmers C, de la Cruz D, Chaix A, Ramos R, Panda S, et al. Local circadian clock gates cell cycle progression of transient amplifying cells during regenerative hair cycling. Proc Natl Acad Sci U S A. 2013;110:E2106–15.
   Google Scholar
• Zhang Y, Chen X, Ren P, Su Z, Cao H, Zhou J, et al. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2013;87:356–62.
   PubMed Web of Science ®Google Scholar
• Shukla P, Gupta D, Bisht SS, Pant MC, Bhatt ML, Gupta R, et al. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. Cancer. 2010;116:2031–5.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Mackenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). Int J Radiat Oncol Biol Phys. 2009;73:166–72.
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 1999;154:613–22.
   PubMed Web of Science ®Google Scholar
• Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S, et al. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. Int J Radiat Biol. 2009;85:504–9.
   PubMed Web of Science ®Google Scholar
• Noh JM, Choi DH, Park H, Huh SJ, Park W, Seol SW, et al. Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. J Radiat Res. 2014;55:553–8.
   PubMed Web of Science ®Google Scholar
• Rahn DA, Ray DK, Schlesinger DJ, Steiner L, Sheehan JP, O’Quigley JM, et al. Gamma knife radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment?Cancer. 2011;117:414–20.
   PubMed Web of Science ®Google Scholar
• Badiyan SN, Ferraro DJ, Yaddanapudi S, Drzymala RE, Lee AY, Silver SA, et al. Impact of time of day on outcomes after stereotactic radiosurgery for non-small cell lung cancer brain metastases. Cancer. 2013;119:3563–9.
   PubMed Web of Science ®Google Scholar
• Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lu. J Clin Oncol. 2005;23:3760–7.
   PubMed Web of Science ®Google Scholar
• Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012;30:2788–97.
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006;368:843–54.
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16.
   PubMed Web of Science ®Google Scholar
• Ortiz-Tudela E, Iurisci I, Beau J, Karaboue A, Moreau T, Rol de Lama MA, et al. The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. Int J Cancer. 2014; 134:2717–25.
   PubMed Web of Science ®Google Scholar
• Savard J, Liu L, Natarajan L, Rissling MB, Neikrug AB, He F, et al. Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep. 2009;32:1155–60.
   PubMed Web of Science ®Google Scholar
• Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. Oncol Nurs Forum. 2010;37:E359–69.
   Google Scholar
• Ancoli-Israel S, Rissling M, Neikrug A, Trofimenko V, Natarajan L, Parker BA, et al. Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer. 2012;20: 1211–19.
   PubMed Web of Science ®Google Scholar
• Li XM, Vincenti M, Levi F. Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol Int. 2002;19:43–55.
   PubMed Web of Science ®Google Scholar
• Li XM, Kanekal S, Crepin D, Guettier C, Carriere J, Elliott G, et al. Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006;5:337–46.
   PubMedGoogle Scholar
• Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med. 2001;7:356–60.
   PubMed Web of Science ®Google Scholar
• Morere JF. Oncology in2012: from personalized medicine to precision medicine. Target Oncol. 2012;7:211–12.
   PubMedGoogle Scholar
• Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099–105.
   PubMed Web of Science ®Google Scholar
• Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48:1676–9.
   PubMed Web of Science ®Google Scholar
• Innominato P, Lévi F, Bjarnason G. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev. 2010; 62:979–1001.
   PubMed Web of Science ®Google Scholar
• Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38:1677–84.
   PubMed Web of Science ®Google Scholar
• Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, et al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 2011;68:301–7.
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14:1233–42.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, et al. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011;28:586–600.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, Focan C, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013;119:2564–73.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can. J Clin Oncol. 2006;24:3562–9.
   PubMed Web of Science ®Google Scholar
• Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103:1165–71.
   PubMed Web of Science ®Google Scholar
• Levi F, Focan C, Karaboue A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007;59:1015–35.
   PubMed Web of Science ®Google Scholar
• Costanzo ES, Stawski RS, Ryff CD, Coe CL, Almeida DM. Cancer survivors’ responses to daily stressors: implications for quality of life. Health Psychol. 2012;31:360–70.
   PubMed Web of Science ®Google Scholar
• Palesh OG, Mustian KM, Peppone LJ, Janelsins M, Sprod LK, Kesler S, et al. Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med. 2012;13:1184–90.
   PubMed Web of Science ®Google Scholar
• Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004;29:1082–92.
   PubMed Web of Science ®Google Scholar
• Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, et al. Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol. 2008;26: 2464–72.
   PubMed Web of Science ®Google Scholar
• Levy S, Herberman R, Lippman M, d’Angelo T. Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer. J Clin Oncol. 1987;5:348–53.
   PubMed Web of Science ®Google Scholar
• Palesh O, Zeitzer JM, Conrad A, Giese-Davis J, Mustian KM, Popek V, et al. Vagal regulation, cortisol, and sleep disruption in women with metastatic breast cancer. J Clin Sleep Med. 2008;4:441–9.
   PubMed Web of Science ®Google Scholar
• Drake CL, Roehrs T, Roth T. Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety. 2003;18:163–76.
   PubMed Web of Science ®Google Scholar
• Dow KH, Ferrell BR, Leigh S, Ly J, Gulasekaram P. An evaluation of the quality of life among long-term survivors of breast cancer. Breast Cancer Res Treat. 1996;39:261–73.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S. Recognition and treatment of sleep disturbances in cancer. J Clin Oncol. 2009;27:5864–6.
   PubMedGoogle Scholar
• Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 2010;70:3351–60.
   PubMed Web of Science ®Google Scholar
• Morin CM, Vallières A, Guay B, Ivers H, Savard J, Mérette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301:2005–15.
   PubMed Web of Science ®Google Scholar
• Harvey AG, Tang NKY. Cognitive behaviour therapy for primary insomnia: can we rest yet?Sleep Med Rev. 2003;7:237–62.
   PubMed Web of Science ®Google Scholar
• Espie CA, Fleming L, Cassidy J, Samuel L, Taylor LM, White CA, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol. 2008;26:4651–8.
   PubMed Web of Science ®Google Scholar
• Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol. 2005;23:6083–96.
   PubMed Web of Science ®Google Scholar
• Barsevick A, Beck SL, Dudley WN, Wong B, Berger AM, Whitmer K, et al. Efficacy of an intervention for fatigue and sleep disturbance during cancer chemotherapy. J Pain Symptom Manag. 2010;40:200–16.
   PubMed Web of Science ®Google Scholar
• Berger AM, Kuhn BR, Farr LA, Von Essen SG, Chamberlain J, Lynch JC, et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol. 2009;27:6033–40.
   PubMed Web of Science ®Google Scholar
• Palesh O, Innominato PF, Mustian K, Janelsins M, Neri E, Koopman C, et al. Brief behavioral therapy for insomnia (BBT-I) in breat cancer during chemotherapy: a randomized pilot study. 2013 MASCC Annual Meeting. Berlin, Germany; 2013.
   Google Scholar
• Berger AM, Wielgus K, Hertzog M, Fischer P, Farr L. Patterns of circadian activity rhythms and their relationships with fatigue and anxiety/depression in women treated with breast cancer adjuvant chemotherapy. Support Care Cancer. 2010;18:105–14.
   PubMed Web of Science ®Google Scholar
• Blacklock R, Rhodes R, Blanchard C, Gaul C. Effects of exercise intensity and self-efficacy on state anxiety with breast cancer survivors. Oncol Nurs Forum. 2010;37:206–12.
   PubMedGoogle Scholar
• Kendall AR, Mahue-Giangreco M, Carpenter CL, Ganz PA, Bernstein L. Influence of exercise activity on quality of life in long-term breast cancer survivors. Qual Life Res. 2005;14:361–71.
   PubMed Web of Science ®Google Scholar
• Dimeo FC, Stieglitz RD, Novelli-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273–7.
   PubMed Web of Science ®Google Scholar
• Mock V, Burke MB, Sheehan P, Creaton EM, Winningham ML, McKenney-Tedder S, et al. A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 1994;21:899–907; discussion 908.
   PubMedGoogle Scholar
• Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293:2479–86.
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006;24:3535–41.
   PubMed Web of Science ®Google Scholar
• Driver HS, Taylor SR. Exercise and sleep. Sleep Med Rev. 2000;4: 387–402.
   PubMed Web of Science ®Google Scholar
• Mustian KM, Griggs JJ, Morrow GR, McTiernan A, Roscoe JA, Bole CW, et al. Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Support Care Cancer. 2006;14:732–41.
   PubMedGoogle Scholar
• Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 2013;31:3233–41.
   PubMed Web of Science ®Google Scholar
• Gronfier C, Wright KP, Kronauer RE, Jewett ME, Czeisler CA. Efficacy of a single sequence of intermittent bright light pulses for delaying circadian phase in humans. Am J Physiol Endocrinol Metab. 2004; 287:E174–81.
   PubMed Web of Science ®Google Scholar
• Benedetti F, Barbini B, Colombo C, Smeraldi E. Chronotherapeutics in a psychiatric ward. Sleep Med Rev. 2007;11:509–22.
   PubMed Web of Science ®Google Scholar
• Neikrug AB, Rissling M, Trofimenko V, Liu L, Natarajan L, Lawton S, et al. Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. Behav Sleep Med. 2012;10:202–16.
   PubMed Web of Science ®Google Scholar
• Marcheva B, Ramsey KM, Peek CB, Affinati A, Maury E, Bass J. Circadian clocks and metabolism. Handb Exp Pharmacol. 2013;(217):127–55.
   PubMedGoogle Scholar
• Challet E. Circadian clocks, food intake, and metabolism. Prog Mol Biol Transl Sci. 2013;119:105–35.
   PubMed Web of Science ®Google Scholar
• Yoshizaki T, Tada Y, Hida A, Sunami A, Yokoyama Y, Togo F, et al. Influence of dietary behavior on the circadian rhythm of the autonomic nervous system as assessed by heart rate variability. Physiol Behav. 2013;118:122–8.
   PubMed Web of Science ®Google Scholar
• Wu MW, Li XM, Xian LJ, Levi F. Effects of meal timing on tumor progression in mice. Life Sci. 2004;75:1181–93.
   PubMed Web of Science ®Google Scholar
• Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M. Entrainment of the circadian clock in the liver by feeding. Science. 2001;291:490–3.
   PubMed Web of Science ®Google Scholar
• Mistlberger RE, Skene DJ. Social influences on mammalian circadian rhythms: animal and human studies. Biol Rev Camb Philos Soc. 2004;79:533–56.
   PubMed Web of Science ®Google Scholar
• Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000;48:593–604.
   PubMed Web of Science ®Google Scholar
• Monk TH, Reynolds CF, Buysse DJ, DeGrazia JM, Kupfer DJ. The relationship between lifestyle regularity and subjective sleep quality. Chronobiol Int. 2003;20:97–107.
   PubMed Web of Science ®Google Scholar
• Swartz HA, Frank E, O’Toole K, Newman N, Kiderman H, Carlson S, et al. Implementing interpersonal and social rhythm therapy for mood disorders across a continuum of care. Psychiatr Serv. 2011; 62:1377–80.
   PubMed Web of Science ®Google Scholar
• Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, et al. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and. J Clin Oncol. 2008;26:2020–6.
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoffski P, et al. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?Eur J Cancer. 2006;42:42–9.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–76.
   PubMedGoogle Scholar
• Schroeder AM, Colwell CS. How to fix a broken clock. Trends Pharmacol Sci. 2013;34:605–19
   PubMed Web of Science ®Google Scholar
• Antoch MP, Kondratov RV. Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy. Handb Exp Pharmacol. 2013;(217):289–309.
   PubMedGoogle Scholar
• Hirota T, Kay SA. High-throughput screening and chemical biology: new approaches for understanding circadian clock mechanisms. Chem Biol. 2009;16:921–7.
   PubMedGoogle Scholar
• Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, et al. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science. 2000;289:2344–7.
   PubMed Web of Science ®Google Scholar
• Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343:1070–7.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205–14.
   PubMed Web of Science ®Google Scholar
• Morris CJ, Aeschbach D, Scheer FAJL. Circadian system, sleep and endocrinology. Mol Cell Endocrinol. 2012;349:91–104.
   PubMed Web of Science ®Google Scholar
• Zhang EE, Liu AC, Hirota T, Miraglia LJ, Welch G, Pongsawakul PY, et al. A genome-wide RNAi screen for modifiers of the circadian clock in human cells. Cell. 2009;139:199–210.
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Liu L, Marler MR, Parker BA, Jones V, Sadler GR, et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006;14(3):201–9.
   PubMedGoogle Scholar
• Berger AM, Farr LA, Kuhn BR, Fischer P, Agrawal S. Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manag. 2007;33: 398–409.
   PubMed Web of Science ®Google Scholar
• Berger AM, Kuhn BR, Farr LA, Lynch JC, Agrawal S, Chamberlain J, et al. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology. 2009;18:634–46.
   PubMed Web of Science ®Google Scholar
• Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum. 1998;25:51–62.
   PubMedGoogle Scholar
• Berger AM, Farr L. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum. 1999;26: 1663–71.
   PubMedGoogle Scholar
• Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum. 2000;27:1443–8.
   PubMedGoogle Scholar
• Kuo HH, Chiu MJ, Liao WC, Hwang SL. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc. 2006;105:64–9.
   PubMed Web of Science ®Google Scholar
• Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, et al. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. Sleep. 2012;35:237–45.
   PubMed Web of Science ®Google Scholar
• Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun. 2012;26:706–13.
   PubMed Web of Science ®Google Scholar
• Liu L, Rissling M, Neikrug A, Fiorentino L, Natarajan L, Faierman M, et al. Fatigue and circadian activity rhythms in breast cancer patients before and after chemotherapy: a controlled study. Fatigue. 2013;1:12–26.
   PubMedGoogle Scholar
• Payne J, Piper B, Rabinowitz I, Zimmerman B. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: a pilot study. Oncol Nurs Forum. 2006;33:775–83.
   PubMed Web of Science ®Google Scholar
• Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Matteson S, Rakita D, et al. Temporal interrelationships among fatigue, circadian rhythm and depression in breast cancer patients undergoing chemotherapy treatment. Support Care Cancer. 2002;10:329–36.
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manag. 1999;17:320–32.
   PubMed Web of Science ®Google Scholar
• Sarna L, Conde F. Physical activity and fatigue during radiation therapy: a pilot study using actigraph monitors. Oncol Nurs Forum. 2001;28:1043–6.
   PubMedGoogle Scholar
• Levin RD, Daehler MA, Grutsch JF, Quiton J, Lis CG, Peterson C, et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer. 2005;93:1202–8.
   PubMed Web of Science ®Google Scholar
• Hinds PS, Hockenberry MJ, Gattuso JS, Srivastava DK, Tong X, Jones H, et al. Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer. 2007;110:2321–30.
   PubMed Web of Science ®Google Scholar
• Vallance K, Liu W, Mandrell BN, Panetta JC, Gattuso JS, Hockenberry M, et al. Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. Eur J Cancer. 2010;46:1848–55.
   PubMed Web of Science ®Google Scholar
• Coleman EA, Goodwin JA, Coon SK, Richards K, Enderlin C, Kennedy R, et al. Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma. Cancer Nurs. 2011;34:219–27.
   PubMed Web of Science ®Google Scholar
• Gholam D, Giacchetti S, Brezault-Bonnet C, Bouchahda M, Hauteville D, Adam R, et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 2006;11:1072–80.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
   PubMed Web of Science ®Google Scholar